The role of < em > CYP2C9*2 < /em > , < em > CYP2C9*3 < /em > and < em > VKORC1- < /em > 1639 variants on the susceptibility of upper gastrointestinal bleeding: A full case-control study

Conclusion: Our findings suggest an increased risk of UGIB in carriers of the variant allele of rs9923231 and in carriers of the *3 allele associated with doses of NSAIDs greater than 0.5. Hence, the assessment of these variants might reduce the incidence of NSAIDs-related UGIB and contribute to the safety of the NSAIDs user.PMID:36942299 | PMC:PMC9990631 | DOI:10.3389/jpps.2023.11136
Source: Journal of Pharmacy and Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Source Type: research